Advertisement

Fungal Infections Among Patients with AIDS

  • Olivier Lortholary
  • Bertrand Dupont
Chapter

Abstract

Fungal infections are the most frequent opportunistic ­diseases occurring during the course of HIV infection. Those mycoses that are usually controlled by cellular immunity are most commonly observed. However, in patients with AIDS, the immune deficit is complex and worsens with time in untreated patients, allowing mycotic diseases to develop [1–3]. Pneumocystis jiroveci and Candida albicans, which are responsible for mucosal candidiasis, and Cryptococcus neoformans, the most frequent cause of meningitis, are the three major fungal pathogens in patients with AIDS [4, 5]. In endemic areas, infections due to dimorphic fungi also ­represent an important group. Histoplasma capsulatum, Coccidioides species, and Penicillium marneffei are the most important endemic pathogens. In some AIDS patients, mycotic disease is often the consequence of reactivation ­several years after a primary infection [6].

Keywords

Invasive Aspergillosis Minimum Inhibitory Concentration Immune Reconstitution Inflammatory Syndrome Cryptococcal Meningitis Cryptococcal Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Spellberg B, Edwards Jr JE. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis. 2001;32:76–102.PubMedCrossRefGoogle Scholar
  2. 2.
    Cunliffe NA, Denning DW. Uncommon invasive mycoses in AIDS. AIDS. 1995;9:411–20.PubMedGoogle Scholar
  3. 3.
    Perfect JR, Schell WA, Rinaldi MG. Uncommon invasive fungal pathogens in the acquired immunodeficiency syndrome. J Med Vet Mycol. 1993;31:175–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jiroveci pneumonia. Infect Dis Clin North Am. 2010;24(1):107–38.PubMedCrossRefGoogle Scholar
  5. 5.
    Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS – 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995;8:515–48.PubMedGoogle Scholar
  6. 6.
    Wheat J. Endemic mycoses in AIDS: a clinical review. Clin Microbiol Rev. 1995;8:146–59.PubMedGoogle Scholar
  7. 7.
    Ampel NM. Emerging disease issues and fungal pathogens associated with HIV infection. Emerg Infect Dis. 1996;2:109–16.PubMedCrossRefGoogle Scholar
  8. 8.
    Dupont B, Crewe Brown HH, Westermann K, et al. Mycoses in AIDS. Med Mycol. 2000;38:259–67.PubMedGoogle Scholar
  9. 9.
    Klein RS, Harris CA, et al. Oral candidiasis in high risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984;311:354–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Sullivan D, Coleman D. Candida dubliniensis: characteristics and identification. J Clin Microbiol. 1998;36:329–34.PubMedGoogle Scholar
  11. 11.
    Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.PubMedCrossRefGoogle Scholar
  12. 12.
    Wilcox CM. Esophageal disease in the acquired immunodeficiency syndrome: etiology, diagnosis, and management. Am J Med. 1992;92:412–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin B for the treatment of candidal esophagitis. Clin Infect Dis. 2001;33:1529–35.PubMedCrossRefGoogle Scholar
  14. 14.
    Ally R, Schürmann, Kreisel W, et al. A randomized, double-blind, double dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33:1447–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Launay O, Lortholary O, Bourges C, Jarrousse B, Bentata M, Guillevin L. Candidemia: a nosocomial complication in adults with late-stage AIDS. Clin Infect Dis. 1998;26:1134–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother. 2006;57:384–410.PubMedCrossRefGoogle Scholar
  17. 17.
    Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;173:219–25.PubMedGoogle Scholar
  18. 18.
    Walmsley S, King S, McGeer A, Ye Y, Richardson S. Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression. Clin Infect Dis. 2001;32:1554–61.PubMedCrossRefGoogle Scholar
  19. 19.
    Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis. 1994;18:240–2.PubMedGoogle Scholar
  20. 20.
    Revankar SG, Dib OP, Kirkpatrick WR, et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;26:960–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Dromer F, Improvisi L, Dupont B, Eliaszewicz M, Pialoux G, Fournier S. Oral transmission of Candida albicans isolates between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates. AIDS. 1997;11:1095–101.PubMedCrossRefGoogle Scholar
  22. 22.
    Kwon-Chung KJ, Varma A, Howard DH. Ecology of Cryptococcus neoformans and prevalence of its two varieties in AIDS and non-AIDS associated cryptococcosis. In: Vanden Bossche H, MacKenzie DWR, Cauwenbergh G, Van Cutsem J, Drouhet E, Dupont B, editors. Mycoses in AIDS patients. New York: Plenum Press; 1990. p. 103–13.Google Scholar
  23. 23.
    Dromer F, Mathoulin-Pélissier S, Fontanet A, et al. Epidemiology of HIV-associated cryptococcosis in France (1985–2001): comparison of the pre- and post-HAART eras. AIDS. 2004;18:555–62.PubMedCrossRefGoogle Scholar
  24. 24.
    Jarvis JN, Dromer F, Harrison TS, Lortholary O. Managing cryptococcosis in the immunocompromised host. Curr Opin Infect Dis. 2008;21:596–603.PubMedCrossRefGoogle Scholar
  25. 25.
    Micol R, Lortholary O, Sar B, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr. 2007;45:555–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Neuville S, Dromer F, Morin O, et al. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis. 2003;6:337–44.CrossRefGoogle Scholar
  28. 28.
    Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O. French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4:e21.PubMedCrossRefGoogle Scholar
  29. 29.
    Charlier C, Dromer F, Lévêque C, et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS ONE. 2008;3:e1950.PubMedCrossRefGoogle Scholar
  30. 30.
    Cameron ML, Bartlett JA, Gallis HA, Waskin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis. 1990;12:768–77.Google Scholar
  31. 31.
    Meyohas MC, Roux P, Bollens D, et al. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis. 1995;21:628–33.PubMedGoogle Scholar
  32. 32.
    Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 Update by the Infectious Disease Society of America. Clin Infect Dis. 2010;50:291–322.PubMedCrossRefGoogle Scholar
  33. 33.
    Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009;48:856–62.PubMedCrossRefGoogle Scholar
  34. 34.
    van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337:15–21.PubMedCrossRefGoogle Scholar
  35. 35.
    Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2009;48:1775–83.PubMedCrossRefGoogle Scholar
  36. 36.
    Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O. French Cryptococcosis Study Group. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One. 2008;3:e2870.PubMedCrossRefGoogle Scholar
  37. 37.
    Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med. 1992;326:83–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS. 1993;7:829–35.PubMedCrossRefGoogle Scholar
  39. 39.
    Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997;11:1463–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Liliang P-C, Liang C-L, Chang W-N, Lu K, Lu C-H. Use of ventriculoperitoneal shunts to treat uncontrollable intracranial hypertension in patients who have cryptococcal meningitis without hydrocephalus. Clin Infect Dis. 2002;34:e64–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis. 2000;30:47–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Aberg JA, Price RW, Heeren DM, Bredt B. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis. 2002;185:1179–82.PubMedCrossRefGoogle Scholar
  43. 43.
    Mussini C, Pezzotti P, Miró JM, et al. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis. 2004;38:565–71.PubMedCrossRefGoogle Scholar
  44. 44.
    Lortholary O, Poizat G, Zeller V, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS. 2006;20:2183–91.PubMedCrossRefGoogle Scholar
  45. 45.
    Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis. 2003;36:1329–31.PubMedCrossRefGoogle Scholar
  46. 46.
    Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Mootsikapun P, Boonyaprawit P. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med. 2004;5:140–3.PubMedCrossRefGoogle Scholar
  47. 47.
    Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet. 1994;334:110–3.CrossRefGoogle Scholar
  48. 48.
    Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore). 1990;69:361–74.Google Scholar
  49. 49.
    Warnock DW, Dupont B, Kauffman CA, Sirisanthana T. Imported mycoses in Europe. Med Mycol. 1998;36:87–94.PubMedGoogle Scholar
  50. 50.
    McKinsey D, Spiegel RA, Hutwagner L, et al. Prospective study of histoplasmosis patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology. Clin Infect Dis. 1997;24:1195–203.PubMedCrossRefGoogle Scholar
  51. 51.
    Wheat J, Chetchotisakd P, Williams B, Connolly P, Shutt K, Hajjeh R. Factors associated with severe manifestations of histoplasmosis in AIDS. Clin Infect Dis. 2000;30:877–81.PubMedCrossRefGoogle Scholar
  52. 52.
    Loulergue P, Bastides F, Baudouin V, et al. Literature review and case histories of Histoplasma capsulatum var. duboisii infections in HIV-infected patients. Emerg Infect Dis. 2007;13:1647–52.PubMedGoogle Scholar
  53. 53.
    Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807–25.PubMedCrossRefGoogle Scholar
  54. 54.
    Goldman M, Zackin R, Fichtenbaum CJ, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis. 2004;38:1485–9.PubMedCrossRefGoogle Scholar
  55. 55.
    McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. Clin Infect Dis. 1999;28:1049–56.PubMedCrossRefGoogle Scholar
  56. 56.
    Bronnimann DA, Adam RD, Galgiani JN, et al. Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann Intern Med. 1987;106:372–9.PubMedGoogle Scholar
  57. 57.
    Woods CW, McRill C, Plikaytis BD, et al. Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994–1997: incidence, risk factors, and prevention. J Infect Dis. 2000;181:1428–34.PubMedCrossRefGoogle Scholar
  58. 58.
    Fish DG, Ampel NM, Galgiani JN, et al. Coccidioides immitis in patients with human immunodeficiency virus infections: a review of 77 patients. Medicine (Baltimore). 1990;69:384–91.Google Scholar
  59. 59.
    Galgiani JN, Ampel NM. Coccidioides immitis in patients with human immunodeficiency virus infections. Semin Respir Infect. 1990;5:151–4.PubMedGoogle Scholar
  60. 60.
    Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis. 2005;41:1217–23.PubMedCrossRefGoogle Scholar
  61. 61.
    Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive non-meningeal coccidioidomycosis. Ann Intern Med. 2000;133:676–86.PubMedGoogle Scholar
  62. 62.
    Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR. 2009;58(RR-11):1–166.Google Scholar
  63. 63.
    Deng Z, Ribas JL, Gibson DW, Connor DH. Infection caused by Penicillium marneffei in China and Southeast Asia: review of eighteen published cases and report of four more Chinese cases. Rev Infect Dis. 1998;10:640–52.Google Scholar
  64. 64.
    Drouhet E. Penicilliosis due to Penicillium marneffei: a new emerging systemic mycosis in AIDS patients travelling or living in Southeast Asia. Review of 44 cases reported in HIV infected patients during the last 5 years compared to 44 cases of non-AIDS patients reported over 20 years. J Mycol Med. 1993;4:195–224.Google Scholar
  65. 65.
    Sobottka I, Albrecht H, Mack D, et al. Systemic Penicillium marneffei infection in a German AIDS patient. Eur J Clin Microbiol Infect Dis. 1996;15:256–69.PubMedCrossRefGoogle Scholar
  66. 66.
    Sirisanthana T, Supparatpinyo K, Periens T, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;26:1107–10.PubMedCrossRefGoogle Scholar
  67. 67.
    Supparatpinyo K, Perriens J, Nelson KE, Srisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med. 1998;339:1739–43.PubMedCrossRefGoogle Scholar
  68. 68.
    Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis. 2002;34:277–84.PubMedCrossRefGoogle Scholar
  69. 69.
    Goldani LZ, Sugar AM. Paracoccidioidomycosis in AIDS: an overview. Clin Infect Dis. 1995;21:1275–81.PubMedGoogle Scholar
  70. 70.
    Benard G, Duarte AJS. Paracoccidioidomycosis: a model for evaluation of the effects of human immunodeficiency virus infection on the natural history of endemic tropical diseases. Clin Infect Dis. 2000;31:1032–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Paniago AM, de Freitas AC, Aguiar ES, et al. Paracoccidioidomycosis in patients with human immunodeficiency virus: review of 12 cases observed in an endemic region in Brazil. J Infect. 2005;51:248–52.PubMedCrossRefGoogle Scholar
  72. 72.
    Pappas PG, Pottage JC, Powderly WG, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1992;116:847–53.PubMedGoogle Scholar
  73. 73.
    Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:1801–12.PubMedCrossRefGoogle Scholar
  74. 74.
    Al-Tawfiq JA, Wools KK. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin Infect Dis. 1998;26:1403–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Rocha MM, Dassin T, Lira R, Lima EL, Severo LC, Londero AT. Sporotrichosis in patients with AIDS: report of case and review. Rev Iber Micol. 2001;18:133–6.Google Scholar
  76. 76.
    Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:1255–65.PubMedCrossRefGoogle Scholar
  77. 77.
    Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med. 1991;324:654–62.PubMedCrossRefGoogle Scholar
  78. 78.
    Khoo S, Denning DW. Aspergillus infection in the acquired immune deficiency syndrome. Clin Infect Dis. 1994;19:541–8.Google Scholar
  79. 79.
    Lortholary O, Meyohas MC, Dupont B, et al. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. Am J Med. 1993;95:177–87.PubMedCrossRefGoogle Scholar
  80. 80.
    Kemper CA, Hostetler JS, Follansbee S, et al. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis. 1993;17:344–52.PubMedGoogle Scholar
  81. 81.
    Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60.PubMedCrossRefGoogle Scholar
  82. 82.
    Smith AG, Bustamante CI, Gilmor GD. Zygomycosis (absidiomycosis) in an AIDS patient. Mycopathologia. 1989;105:7–10.PubMedCrossRefGoogle Scholar
  83. 83.
    Vesa J, Bielsa O, Arango O, Liado C, Gelabert A. Massive renal infarction due to mycormycosis in an AIDS patient. Infection. 1992;20:234–6.PubMedCrossRefGoogle Scholar
  84. 84.
    Santos J, Espigado P, Romero C, Andreu J, Rivero A, Pineda JA. Isolated renal mucormycosis in two AIDS patients. Eur J Clin Microbiol Infect Dis. 1994;13:430–2.PubMedCrossRefGoogle Scholar
  85. 85.
    Micozzi MS, Wetli CV. Intravenous amphetamine abuse, primary cerebral mucormycosis, and acquired immunodeficiency. J Forensic Sci. 1985;30:504–10.PubMedGoogle Scholar
  86. 86.
    Cuadrado LM, Guerrero A, Garcia Asenjo JAL, Martin F, Palau E, Urra DG. Cerebral mucormycosis in two cases of acquired immunodeficiency syndrome. Arch Neurol. 1998;45:109–11.Google Scholar
  87. 87.
    Blatt SP, Lucey DR, De Hoff D, Zellmer RB. Rhinocerebral zygomycosis in a patient with AIDS. J Infect Dis. 1991;164:215–6.PubMedGoogle Scholar
  88. 88.
    Hopwood V, Hicks DA, Thomas S, Evans EGV. Primary cutaneous zygomycosis due to Absidia corymbifera in a patient with AIDS. J Med Vet Mycol. 1992;30:399–402.PubMedCrossRefGoogle Scholar
  89. 89.
    Mostaza JM, Barbado FJ, Fernandez-Martin J, Pena-Yanez J, Vasquez-Rodriguez JJ. Cutaneoarticular mucormycosis due to Cunninghamella bertholletiae in a patient with AIDS. Rev Infect Dis. 1989;11:316–8.PubMedGoogle Scholar
  90. 90.
    Chavanet P, Lefranc T, Bonnin A, Waldner A, Portier H. Unusual cause of pharyngeal ulcerations in AIDS. Lancet. 1990;336:383–4.PubMedCrossRefGoogle Scholar
  91. 91.
    Rollot F, Blanche P, Richaud-Thiriez B, et al. Pneumonia due to Scedosporium apiospermum in a patient with HIV infection. Scand J Infect Dis. 2000;32:439.PubMedCrossRefGoogle Scholar
  92. 92.
    Raffanti SP, Fyfe B, Carreiro S, Sharp SE, Hyma BA, Ratzan KR. Native valve endocarditis due to Pseudallescheria boydii in a patient with AIDS: case report and review. Rev Infect Dis. 1990;12:993–6.PubMedGoogle Scholar
  93. 93.
    Montero A, Cohen JE, Fernandez MA, Mazzolini G, Gomez R, Perugini J. Cerebral pseudallescheriasis due to Pseudallescheria boydii as the first manifestation in AIDS. Clin Infect Dis. 1998;26:1476–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Eckburg PB, Zolopa AR, Montoya JG. Invasive fungal sinusitis due to Scedosporium apiospermum in a patient with AIDS. Clin Infect Dis. 1999;29:212–3.PubMedCrossRefGoogle Scholar
  95. 95.
    Scherr GR, Evans SG, Kiyabu MT, Klatt EC. Pseudallescheria boydii infection in the acquired immunodeficiency syndrome. Arch Pathol Lab Med. 1992;116:535–6.PubMedGoogle Scholar
  96. 96.
    Wiest PM, Wiese K, Jacobs MR, et al. Alternaria infection in a patient with acquired immunodeficiency syndrome: case report and review of invasive Alternaria infections. Rev Infect Dis. 1987;9:799–803.PubMedGoogle Scholar
  97. 97.
    Turner D, Burke M, Bashe E, Blinder S, Yust I. Pulmonary adiaspiromycosis in a patient with acquired immunodeficiency syndrome. Eur J Clin Microbiol Infect Dis. 1999;18:893–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Echavarria E, Cano EL, Restrepo A. Disseminated adiaspiromycosis in a patient with AIDS. J Med Vet Mycol. 1993;31:91–7.PubMedCrossRefGoogle Scholar
  99. 99.
    Gori S, Drouhet E, Gueho E, et al. Cutaneous disseminated mycosis in a patient with AIDS due to a new dimorphic fungus. J Mycol Med. 1998;8:57–63.Google Scholar
  100. 100.
    Bossi P, Mortier E, Michon C, et al. Sinusite à Fusarium solani chez un patient atteint de SIDA. J Mycol Med. 1995;5:56–7.Google Scholar
  101. 101.
    Del Palacio-Hernanz A, Casado VA, Lopez FP, Quiros HO, Palancar MP. Infeccion oportunista pulmonar por Fusarium moniliforme en paciente con SIDA. Rev Iber Micol. 1989;6:144–7.Google Scholar
  102. 102.
    Paugam A, Baixench MT, Frank N, et al. Localized oral Fusarium in an AIDS patient with malignant lymphoma. J Infect. 1999;39:153–4.PubMedCrossRefGoogle Scholar
  103. 103.
    Marriott DJE, Wong KH, Aznar E, Harkness JL, Cooper DA, Muir D. Scytalidium dimidiatum and Lecythophora hoffmannii: unusual causes of fungal infections in a patient with AIDS. J Clin Microbiol. 1997;35:2949–52.PubMedGoogle Scholar
  104. 104.
    Rosenthal J, Katz R, Dubois DB, Morrissey A, Machicao A. Chronic maxillary sinusitis associated with the mushroom Schizophyllum commune in a patient with AIDS. Clin Infect Dis. 1992;14:46–8.PubMedGoogle Scholar
  105. 105.
    Al-Tawfik OW, Papasian CJ, Dixon AY, Potter LM. Saccharomyces cerevisiae pneumonia in a patient with acquired immune deficiency syndrome. J Clin Microbiol. 1989;27:1689–91.Google Scholar
  106. 106.
    Lui AY, Turett GS, Karter DL, Bellman PC, Kislak JW. Amphotericin B lipid complex therapy in AIDS patient with Rhodotorula rubra fungemia. Clin Infect Dis. 1998;27:892–3.PubMedCrossRefGoogle Scholar
  107. 107.
    Barchiesi F, Morbiducci V, Ancarani F, Arzeni D, Scalise G. Trichosporon beigelii fungaemia in an AIDS patient. AIDS. 1993;7:139–40.PubMedCrossRefGoogle Scholar
  108. 108.
    Leaf HL, Simberkoff MS. Invasive trichosporonosis in a patient with acquired immunodeficiency syndrome. J Infect Dis. 1989;160:356–7.PubMedGoogle Scholar
  109. 109.
    Parsonnet J. Trichosporon beigelii peritonitis. South Med J. 1989;82:1062–3.PubMedGoogle Scholar
  110. 110.
    Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS. 2001;15:347–55.PubMedCrossRefGoogle Scholar
  111. 111.
    Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60.PubMedCrossRefGoogle Scholar
  112. 112.
    Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, Gonzalez-Lahoz J. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2000;14:383–6.PubMedCrossRefGoogle Scholar
  113. 113.
    Sempowski GD, Haynes BF. Immune reconstitution in patients with HIV infection. Ann Rev Med. 2002;53:269–84.PubMedCrossRefGoogle Scholar
  114. 114.
    Blanche PH, Gombert B, Ginsburg CH, et al. HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy. Scand J Infect Dis. 1998;30:615–6.PubMedCrossRefGoogle Scholar
  115. 115.
    De Simonne JA, Roger J, Pomerantz A, Babinchak TJ. Inflammatory reactions in HIV1-infected persons after initiation of active antiretroviral therapy. Ann Intern Med. 2000;133:447–54.Google Scholar
  116. 116.
    Cheng VCC, Yuen K-Y, Chan W-M, Wong SSY, Ma ESK, Chan RMT. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis. 2000;30:882–92.PubMedCrossRefGoogle Scholar
  117. 117.
    Lortholary O, Fontanet A, Mémain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005;19:1043–9.PubMedCrossRefGoogle Scholar
  118. 118.
    Breton G, Adle-Biassette H, Therby A, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS. 2006;20:119–21.PubMedCrossRefGoogle Scholar
  119. 119.
    Shelburne SA, Darcourt J, White Jr AC, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:1049–52.PubMedCrossRefGoogle Scholar
  120. 120.
    Sungkanuparph S, Filler SG, Chetchotisakd P, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis. 2009;49:931–4.PubMedCrossRefGoogle Scholar
  121. 121.
    Woods ML, MacGinly R, Eisen DP, Allworth AM. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS. 1998;12:1491–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Infectious and Tropical Diseases Departement, Centre d’ Infectiologie Necker-PasteurUniversité Paris Descartes, Hôpital Necker Enfants maladesParisFrance

Personalised recommendations